Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MK-0482 |
Synonyms | |
Therapy Description |
MK-0482 binds to ILT3 and prevents binding of ILT-3 ligands, leading to inhibition of ILT-3 dependent signaling, which may lead to increased antitumor immune response (J Clin Oncol 42, 2024 (suppl 16; abstr 2046), NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MK-0482 | MK 0482|MK0482 | MK-0482 binds to ILT3 and prevents binding of ILT-3 ligands, leading to inhibition of ILT-3 dependent signaling, which may lead to increased antitumor immune response (J Clin Oncol 42, 2024 (suppl 16; abstr 2046), NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05038800 | Phase I | MK-0482 | A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) (MK-0482-002) | Terminated | USA | ISR | ESP | 0 |
NCT03918278 | Phase I | MK-0482 MK-0482 + Pembrolizumab | A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001) | Active, not recruiting | USA | ITA | ISR | ESP | CAN | AUS | 2 |